25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ZLD (Zelira Therapeutics Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Zelira Therapeutics Ltd together

I guess you are interested in Zelira Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Zelira Therapeutics Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Zelira Therapeutics Ltd’s Price Targets

I'm going to help you getting a better view of Zelira Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Zelira Therapeutics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Zelira Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$-0.35
Expected worth in 1 year
A$-12.42
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
A$-12.07
Return On Investment
-2,437.4%

For what price can you sell your share?

Current Price per Share
A$0.50
Expected price per share
A$0.28 - A$0.51
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Zelira Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)
A$0.50
Intrinsic Value Per Share
A$-5.79 - A$2.05
Total Value Per Share
A$-6.14 - A$1.70

2.2. Growth of Zelira Therapeutics Ltd (5 min.)




Is Zelira Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?-$2.6m$20.3m-$23m-859.9%

How much money is Zelira Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$23.4m-$3.5m-$19.9m-84.8%
Net Profit Margin-38,513.0%-1,850.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Zelira Therapeutics Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Zelira Therapeutics Ltd?

Welcome investor! Zelira Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Zelira Therapeutics Ltd.

First you should know what it really means to hold a share of Zelira Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zelira Therapeutics Ltd is A$0.495. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zelira Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zelira Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.35. Based on the TTM, the Book Value Change Per Share is A$-3.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zelira Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-1.98-399.0%-1.98-399.0%-0.30-60.8%-0.97-196.7%-0.75-152.0%-0.45-89.9%
Usd Book Value Change Per Share-1.94-391.6%-1.94-391.6%-0.21-43.4%-0.76-152.8%-0.08-15.9%-0.03-5.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.059.4%
Usd Total Gains Per Share-1.94-391.6%-1.94-391.6%-0.21-43.4%-0.76-152.8%-0.08-15.9%0.024.0%
Usd Price Per Share0.18-0.18-0.97-0.59-0.37-0.20-
Price to Earnings Ratio-0.09--0.09--3.22--1.43--0.89--0.55-
Price-to-Total Gains Ratio-0.09--0.09--4.52--3.33--1.97--1.08-
Price to Book Ratio-0.80--0.80-0.57-0.03-0.02-0.04-
Price-to-Total Gains Ratio-0.09--0.09--4.52--3.33--1.97--1.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.318087
Number of shares3143
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.94-0.08
Usd Total Gains Per Share-1.94-0.08
Gains per Quarter (3143 shares)-6,091.90-247.21
Gains per Year (3143 shares)-24,367.61-988.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-24368-243780-989-999
20-48735-487460-1978-1988
30-73103-731140-2967-2977
40-97470-974820-3955-3966
50-121838-1218500-4944-4955
60-146206-1462180-5933-5944
70-170573-1705860-6922-6933
80-194941-1949540-7911-7922
90-219308-2193220-8900-8911
100-243676-2436900-9888-9900

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%2.018.01.09.5%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.011.00.047.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%3.00.018.014.3%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%3.07.00.030.0%10.011.00.047.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Zelira Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.016-3.0160%-0.334-89%-1.177-61%-0.122-96%-0.041-99%
Book Value Per Share---0.351-0.3510%2.665-113%1.772-120%2.280-115%1.286-127%
Current Ratio--0.6010.6010%0.940-36%1.554-61%2.612-77%19.856-97%
Debt To Asset Ratio--1.8051.8050%0.064+2708%0.641+182%0.399+352%0.558+224%
Debt To Equity Ratio----0%0.069-100%0.042-100%0.040-100%0.050-100%
Dividend Per Share----0%-0%-0%-0%0.072-100%
Enterprise Value---5439210.000-5439210.0000%15932065.000-134%7589531.667-172%5562602.080-198%4642410.680-217%
Eps---3.074-3.0740%-0.468-85%-1.515-51%-1.171-62%-0.693-77%
Ev To Ebitda Ratio--0.1490.1490%-2.320+1654%-1.043+798%-0.740+596%0.317-53%
Ev To Sales Ratio---57.284-57.2840%52.909-208%1.198-4882%2.240-2658%4.098-1498%
Free Cash Flow Per Share---0.369-0.3690%-0.609+65%-0.590+60%-0.616+67%-0.382+4%
Free Cash Flow To Equity Per Share---0.039-0.0390%-0.461+1079%-0.232+493%-0.148+279%-0.030-23%
Gross Profit Margin--1.0011.0010%1.013-1%1.025-2%1.053-5%1.101-9%
Intrinsic Value_10Y_max--2.052----------
Intrinsic Value_10Y_min---5.785----------
Intrinsic Value_1Y_max---0.256----------
Intrinsic Value_1Y_min---0.613----------
Intrinsic Value_3Y_max---0.417----------
Intrinsic Value_3Y_min---1.824----------
Intrinsic Value_5Y_max---0.155----------
Intrinsic Value_5Y_min---3.006----------
Market Cap5889114.000+43%3331216.0003331216.0000%17964772.000-81%10945424.000-70%6798060.080-51%3651250.680-9%
Net Profit Margin---385.130-385.1300%-18.508-95%-137.131-64%-86.971-77%-84.170-78%
Operating Margin---388.830-388.8300%-24.617-94%-140.718-64%-89.749-77%-85.402-78%
Operating Ratio--63.53963.5390%25.617+148%32.955+93%25.247+152%54.573+16%
Pb Ratio-1.411-77%-0.798-0.7980%0.567-241%0.031-2714%0.025-3326%0.037-2274%
Pe Ratio-0.161-77%-0.091-0.0910%-3.224+3439%-1.427+1466%-0.886+873%-0.548+502%
Price Per Share0.495+43%0.2800.2800%1.510-81%0.920-70%0.571-51%0.307-9%
Price To Free Cash Flow Ratio-1.342-77%-0.759-0.7590%-2.478+226%-1.487+96%-0.923+22%-0.586-23%
Price To Total Gains Ratio-0.164-77%-0.093-0.0930%-4.515+4764%-3.334+3492%-1.965+2017%-1.076+1059%
Quick Ratio--0.1110.1110%0.077+44%0.678-84%1.816-94%19.424-99%
Return On Assets---7.055-7.0550%-0.164-98%-2.512-64%-1.590-77%-2.107-70%
Return On Equity----0%-0.1750%-0.1720%-0.1890%-0.4050%
Total Gains Per Share---3.016-3.0160%-0.334-89%-1.177-61%-0.122-96%0.031-9905%
Usd Book Value---2681679.042-2681679.0420%20378002.680-113%13543687.786-120%17428048.677-115%9830467.939-127%
Usd Book Value Change Per Share---1.938-1.9380%-0.215-89%-0.756-61%-0.079-96%-0.027-99%
Usd Book Value Per Share---0.225-0.2250%1.713-113%1.138-120%1.465-115%0.826-127%
Usd Dividend Per Share----0%-0%-0%-0%0.046-100%
Usd Enterprise Value---3495236.346-3495236.3460%10237944.969-134%4877033.049-172%3574528.097-198%2983213.103-217%
Usd Eps---1.975-1.9750%-0.301-85%-0.974-51%-0.752-62%-0.445-77%
Usd Free Cash Flow---2820107.934-2820107.9340%-4658257.523+65%-4512099.866+60%-4708166.723+67%-2921515.740+4%
Usd Free Cash Flow Per Share---0.237-0.2370%-0.392+65%-0.379+60%-0.396+67%-0.246+4%
Usd Free Cash Flow To Equity Per Share---0.025-0.0250%-0.296+1079%-0.149+493%-0.095+279%-0.019-23%
Usd Market Cap3784344.656+43%2140639.4022140639.4020%11544162.487-81%7033529.462-70%4368433.407-51%2346293.687-9%
Usd Price Per Share0.318+43%0.1800.1800%0.970-81%0.591-70%0.367-51%0.197-9%
Usd Profit---23499177.710-23499177.7100%-3581214.298-85%-11585481.239-51%-8951589.960-62%-5252258.777-78%
Usd Revenue--61016.15561016.1550%193500.355-68%414840.497-85%419403.043-85%312687.168-80%
Usd Total Gains Per Share---1.938-1.9380%-0.215-89%-0.756-61%-0.079-96%0.020-9905%
 EOD+6 -2MRQTTM+0 -0YOY+11 -263Y+10 -275Y+10 -2710Y+8 -31

3.3 Fundamental Score

Let's check the fundamental score of Zelira Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.161
Price to Book Ratio (EOD)Between0-1-1.411
Net Profit Margin (MRQ)Greater than0-385.130
Operating Margin (MRQ)Greater than0-388.830
Quick Ratio (MRQ)Greater than10.111
Current Ratio (MRQ)Greater than10.601
Debt to Asset Ratio (MRQ)Less than11.805
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-7.055
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.759
Ma 20Greater thanMa 500.417
Ma 50Greater thanMa 1000.441
Ma 100Greater thanMa 2000.497
OpenGreater thanClose0.500
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Zelira Therapeutics Ltd

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Fundamental data was last updated by Penke on 2025-05-20 17:04:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Zelira Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -38,513.0% means that $-385.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -38,513.0%. The company is making a huge loss. -2
  • The TTM is -38,513.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-38,513.0%TTM-38,513.0%0.0%
TTM-38,513.0%YOY-1,850.8%-36,662.3%
TTM-38,513.0%5Y-8,697.1%-29,815.9%
5Y-8,697.1%10Y-8,417.0%-280.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38,513.0%-84.4%-38,428.6%
TTM-38,513.0%-169.6%-38,343.4%
YOY-1,850.8%-193.2%-1,657.6%
3Y-13,713.1%-253.9%-13,459.2%
5Y-8,697.1%-345.1%-8,352.0%
10Y-8,417.0%-474.1%-7,942.9%
4.3.1.2. Return on Assets

Shows how efficient Zelira Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • -705.5% Return on Assets means that Zelira Therapeutics Ltd generated $-7.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zelira Therapeutics Ltd:

  • The MRQ is -705.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -705.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-705.5%TTM-705.5%0.0%
TTM-705.5%YOY-16.4%-689.1%
TTM-705.5%5Y-159.0%-546.5%
5Y-159.0%10Y-210.7%+51.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-705.5%-11.2%-694.3%
TTM-705.5%-11.4%-694.1%
YOY-16.4%-11.1%-5.3%
3Y-251.2%-11.6%-239.6%
5Y-159.0%-12.2%-146.8%
10Y-210.7%-14.0%-196.7%
4.3.1.3. Return on Equity

Shows how efficient Zelira Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • 0.0% Return on Equity means Zelira Therapeutics Ltd generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-17.5%+17.5%
TTM-5Y-18.9%+18.9%
5Y-18.9%10Y-40.5%+21.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.0%+14.0%
TTM--14.5%+14.5%
YOY-17.5%-14.7%-2.8%
3Y-17.2%-17.1%-0.1%
5Y-18.9%-17.5%-1.4%
10Y-40.5%-19.7%-20.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Zelira Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Zelira Therapeutics Ltd is operating .

  • Measures how much profit Zelira Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -38,883.0% means the company generated $-388.83  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -38,883.0%. The company is operating very inefficient. -2
  • The TTM is -38,883.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-38,883.0%TTM-38,883.0%0.0%
TTM-38,883.0%YOY-2,461.7%-36,421.3%
TTM-38,883.0%5Y-8,974.9%-29,908.2%
5Y-8,974.9%10Y-8,540.2%-434.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38,883.0%-189.1%-38,693.9%
TTM-38,883.0%-300.6%-38,582.4%
YOY-2,461.7%-208.4%-2,253.3%
3Y-14,071.8%-235.8%-13,836.0%
5Y-8,974.9%-350.5%-8,624.4%
10Y-8,540.2%-449.7%-8,090.5%
4.3.2.2. Operating Ratio

Measures how efficient Zelira Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 63.54 means that the operating costs are $63.54 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 63.539. The company is inefficient in keeping operating costs low. -1
  • The TTM is 63.539. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ63.539TTM63.5390.000
TTM63.539YOY25.617+37.922
TTM63.5395Y25.247+38.293
5Y25.24710Y54.573-29.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ63.5392.060+61.479
TTM63.5392.936+60.603
YOY25.6173.030+22.587
3Y32.9553.729+29.226
5Y25.2474.834+20.413
10Y54.5736.406+48.167
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Zelira Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.60 means the company has $0.60 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.601. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.601. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.601TTM0.6010.000
TTM0.601YOY0.940-0.340
TTM0.6015Y2.612-2.011
5Y2.61210Y19.856-17.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6013.602-3.001
TTM0.6013.930-3.329
YOY0.9404.255-3.315
3Y1.5544.778-3.224
5Y2.6125.833-3.221
10Y19.8566.209+13.647
4.4.3.2. Quick Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.11 means the company can pay off $0.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.111. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.111. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.111TTM0.1110.000
TTM0.111YOY0.077+0.034
TTM0.1115Y1.816-1.706
5Y1.81610Y19.424-17.607
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1112.872-2.761
TTM0.1113.417-3.306
YOY0.0774.024-3.947
3Y0.6784.605-3.927
5Y1.8165.882-4.066
10Y19.4246.528+12.896
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Zelira Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Zelira Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zelira Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.81 means that Zelira Therapeutics Ltd assets are financed with 180.5% credit (debt) and the remaining percentage (100% - 180.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 1.805. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.805. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.805TTM1.8050.000
TTM1.805YOY0.064+1.741
TTM1.8055Y0.399+1.406
5Y0.39910Y0.558-0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8050.342+1.463
TTM1.8050.346+1.459
YOY0.0640.335-0.271
3Y0.6410.331+0.310
5Y0.3990.353+0.046
10Y0.5580.379+0.179
4.5.4.2. Debt to Equity Ratio

Measures if Zelira Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.069-0.069
TTM-5Y0.040-0.040
5Y0.04010Y0.050-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.410-0.410
TTM-0.428-0.428
YOY0.0690.415-0.346
3Y0.0420.434-0.392
5Y0.0400.459-0.419
10Y0.0500.498-0.448
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zelira Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.09 means the investor is paying $-0.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -0.161. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.091. Based on the earnings, the company is expensive. -2
  • The TTM is -0.091. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.161MRQ-0.091-0.070
MRQ-0.091TTM-0.0910.000
TTM-0.091YOY-3.224+3.132
TTM-0.0915Y-0.886+0.795
5Y-0.88610Y-0.548-0.338
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.161-1.792+1.631
MRQ-0.091-2.336+2.245
TTM-0.091-2.883+2.792
YOY-3.224-3.425+0.201
3Y-1.427-4.006+2.579
5Y-0.886-6.234+5.348
10Y-0.548-6.709+6.161
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.342. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.759. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.759. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.342MRQ-0.759-0.583
MRQ-0.759TTM-0.7590.000
TTM-0.759YOY-2.478+1.719
TTM-0.7595Y-0.923+0.164
5Y-0.92310Y-0.586-0.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.342-2.621+1.279
MRQ-0.759-3.120+2.361
TTM-0.759-3.779+3.020
YOY-2.478-4.126+1.648
3Y-1.487-5.271+3.784
5Y-0.923-8.214+7.291
10Y-0.586-9.113+8.527
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Zelira Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.80 means the investor is paying $-0.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.411. Based on the equity, the company is expensive. -2
  • The MRQ is -0.798. Based on the equity, the company is expensive. -2
  • The TTM is -0.798. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.411MRQ-0.798-0.613
MRQ-0.798TTM-0.7980.000
TTM-0.798YOY0.567-1.365
TTM-0.7985Y0.025-0.823
5Y0.02510Y0.037-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.4111.819-3.230
MRQ-0.7982.078-2.876
TTM-0.7982.357-3.155
YOY0.5672.417-1.850
3Y0.0312.716-2.685
5Y0.0253.661-3.636
10Y0.0374.303-4.266
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zelira Therapeutics Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Total Stockholder Equity 34,5473,28337,830-2,62635,203-3,40131,802-36,317-4,515
Long-term Assets Other  -33,848672-33,176614-32,561485-32,07632,731655
Gross Profit  -275236-39-5,677-5,7162,500-3,2163,22610



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets5,183
Total Liabilities9,357
Total Stockholder Equity-4,515
 As reported
Total Liabilities 9,357
Total Stockholder Equity+ -4,515
Total Assets = 5,183

Assets

Total Assets5,183
Total Current Assets4,260
Long-term Assets923
Total Current Assets
Cash And Cash Equivalents 586
Net Receivables 198
Inventory 1,252
Other Current Assets 2,224
Total Current Assets  (as reported)4,260
Total Current Assets  (calculated)4,260
+/-0
Long-term Assets
Property Plant Equipment 225
Long Term Investments 43
Intangible Assets 655
Long-term Assets  (as reported)923
Long-term Assets  (calculated)923
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,093
Long-term Liabilities2,263
Total Stockholder Equity-4,515
Total Current Liabilities
Short-term Debt 3,686
Short Long Term Debt 3,540
Accounts payable 3,407
Other Current Liabilities 146
Total Current Liabilities  (as reported)7,093
Total Current Liabilities  (calculated)10,780
+/- 3,686
Long-term Liabilities
Long term Debt 2,114
Capital Lease Obligations 296
Long-term Liabilities  (as reported)2,263
Long-term Liabilities  (calculated)2,409
+/- 146
Total Stockholder Equity
Common Stock45,516
Retained Earnings -81,336
Accumulated Other Comprehensive Income 31,305
Total Stockholder Equity (as reported)-4,515
Total Stockholder Equity (calculated)-4,515
+/-0
Other
Capital Stock45,516
Cash and Short Term Investments 586
Common Stock Shares Outstanding 11,347
Liabilities and Stockholders Equity 5,183
Net Debt 5,363
Net Invested Capital 1,139
Net Working Capital -2,833
Property Plant and Equipment Gross 225
Short Long Term Debt Total 5,949



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-30
> Total Assets 
8,542
10,023
26,451
9,272
1,399
3,547
695
875
1,431
1,078
780
408
88
7,967
6,314
3,515
35,789
39,366
37,701
33,891
5,183
5,18333,89137,70139,36635,7893,5156,3147,967884087801,0781,4318756953,5471,3999,27226,45110,0238,542
   > Total Current Assets 
2,512
1,790
8,618
9,272
1,125
3,453
430
805
1,347
973
599
333
88
7,967
5,777
3,125
1,833
6,090
5,076
1,771
4,260
4,2601,7715,0766,0901,8333,1255,7777,967883335999731,3478054303,4531,1259,2728,6181,7902,512
       Cash And Cash Equivalents 
2,152
1,460
1,962
229
1,094
2,708
343
788
1,279
969
598
325
56
7,868
5,686
3,073
1,697
4,971
2,746
146
586
5861462,7464,9711,6973,0735,6867,868563255989691,2797883432,7081,0942291,9621,4602,152
       Short-term Investments 
0
0
5,375
0
0
619
0
0
0
0
0
0
0
0
0
0
-108
-100
0
0
0
000-100-1080000000000619005,37500
       Net Receivables 
110
80
709
1,108
29
742
87
17
69
4
2
9
32
95
67
33
63
57
256
-1
198
198-1256576333679532924691787742291,10870980110
       Inventory 
250
250
365
4,259
1
1
0
0
0
0
0
0
-39
-95
-67
-33
-64
868
1,957
1,528
1,252
1,2521,5281,957868-64-33-67-95-39000000114,259365250250
   > Long-term Assets 
6,030
8,233
17,833
0
274
94
265
70
84
105
181
75
0
0
537
391
33,956
33,275
32,625
32,120
923
92332,12032,62533,27533,9563915370075181105847026594274017,8338,2336,030
       Property Plant Equipment 
4,974
7,177
17,811
0
274
94
68
70
84
105
181
75
0
0
0
33
1,580
1,239
848
519
225
2255198481,2391,580330007518110584706894274017,8117,1774,974
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,747
30,747
30,747
30,747
30,747
0
030,74730,74730,74730,74730,747000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
537
358
350
167
64
43
43
43436416735035853700000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,026
32,026
31,870
31,714
31,558
655
65531,55831,71431,87032,02632,026000000000000000
       Other Assets 
1,056
1,056
21
0
0
0
0
0
0
0
0
58
0
0
0
0
108
100
0
0
0
00010010800005800000000211,0561,056
> Total Liabilities 
252
143
11,576
24,116
123
1,069
41
214
79
38
30
50
290
71
99
407
1,242
1,536
2,011
2,179
9,357
9,3572,1792,0111,5361,242407997129050303879214411,06912324,11611,576143252
   > Total Current Liabilities 
252
143
8,030
24,116
123
271
41
214
79
38
30
50
290
71
99
407
670
1,076
1,627
1,884
7,093
7,0931,8841,6271,0766704079971290503038792144127112324,1168,030143252
       Short-term Debt 
0
0
2,848
3,317
0
0
0
0
0
0
0
0
1,000
0
0
61
61
91
117
143
3,686
3,686143117916161001,000000000003,3172,84800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
3,540
3,54000000001,000000000000000
       Accounts payable 
57
59
2,692
18,646
98
212
41
214
79
38
30
50
45
71
99
407
559
985
1,510
1,741
3,407
3,4071,7411,51098555940799714550303879214412129818,6462,6925957
       Other Current Liabilities 
195
84
2,490
2,152
25
59
0
214
79
38
30
50
1,045
0
0
50
50
91
117
143
146
146143117915050001,04550303879214059252,1522,49084195
   > Long-term Liabilities 
0
0
3,546
0
0
798
0
0
0
0
0
0
0
0
0
571
571
461
384
295
2,263
2,263295384461571571000000000798003,54600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
571
461
384
295
0
02953844615710000000000000000
       Other Liabilities 
0
0
3,262
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000003,26200
> Total Stockholder Equity
8,290
9,879
14,875
-14,843
1,276
2,478
654
661
1,352
1,040
750
358
-203
7,897
6,214
3,108
34,547
37,830
35,203
31,802
-4,515
-4,51531,80235,20337,83034,5473,1086,2147,897-2033587501,0401,3526616542,4781,276-14,84314,8759,8798,290
   Common Stock
8,402
10,303
14,428
24,820
28,325
14,947
14,947
14,947
15,962
15,962
15,962
15,970
16,308
13,803
13,823
13,823
26,076
36,651
43,746
45,516
45,516
45,51645,51643,74636,65126,07613,82313,82313,80316,30815,97015,96215,96215,96214,94714,94714,94728,32524,82014,42810,3038,402
   Retained Earnings -81,336-44,767-39,194-27,249-18,700-11,680-8,112-6,382-16,510-15,612-15,526-19,141-18,829-18,191-18,198-20,736-27,048-39,663-1,501-424-112
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
4,219
314
0
0
475
503
965
27,171
28,427
30,651
-570
0
0-57030,65128,42727,171965503475003144,219000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue95
Cost of Revenue-85
Gross Profit1010
 
Operating Income (+$)
Gross Profit10
Operating Expense-5,949
Operating Income-5,938-5,938
 
Operating Expense (+$)
Research Development2,810
Selling General Administrative1,337
Selling And Marketing Expenses28
Operating Expense5,9494,175
 
Net Interest Income (+$)
Interest Income0
Interest Expense-739
Other Finance Cost-0
Net Interest Income-739
 
Pretax Income (+$)
Operating Income-5,938
Net Interest Income-739
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,65925,783
EBIT - interestExpense = -37,659
-37,489
-35,830
Interest Expense739
Earnings Before Interest and Taxes (EBIT)-36,920-36,920
Earnings Before Interest and Taxes (EBITDA)-36,441
 
After tax Income (+$)
Income Before Tax-37,659
Tax Provision-0
Net Income From Continuing Ops-36,740-37,659
Net Income-36,569
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,504
Total Other Income/Expenses Net-31,721739
 

Technical Analysis of Zelira Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zelira Therapeutics Ltd. The general trend of Zelira Therapeutics Ltd is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zelira Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Zelira Therapeutics Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zelira Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.5 < 0.51 < 0.51.

The bearish price targets are: 0.37 > 0.345 > 0.28.

Know someone who trades $ZLD? Share this with them.👇

Zelira Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zelira Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zelira Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zelira Therapeutics Ltd. The current macd is 0.01120895.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zelira Therapeutics Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zelira Therapeutics Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zelira Therapeutics Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Zelira Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartZelira Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zelira Therapeutics Ltd. The current adx is 30.23.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zelira Therapeutics Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Zelira Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zelira Therapeutics Ltd. The current sar is 0.38913568.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Zelira Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zelira Therapeutics Ltd. The current rsi is 63.76. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Zelira Therapeutics Ltd Daily Relative Strength Index (RSI) ChartZelira Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zelira Therapeutics Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zelira Therapeutics Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Zelira Therapeutics Ltd Daily Stochastic Oscillator ChartZelira Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zelira Therapeutics Ltd. The current cci is 154.84.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Zelira Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartZelira Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zelira Therapeutics Ltd. The current cmo is 37.65.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Zelira Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartZelira Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zelira Therapeutics Ltd. The current willr is -16.66666667.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Zelira Therapeutics Ltd Daily Williams %R ChartZelira Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zelira Therapeutics Ltd.

Zelira Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zelira Therapeutics Ltd. The current atr is 0.02485272.

Zelira Therapeutics Ltd Daily Average True Range (ATR) ChartZelira Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zelira Therapeutics Ltd. The current obv is -328,935.

Zelira Therapeutics Ltd Daily On-Balance Volume (OBV) ChartZelira Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zelira Therapeutics Ltd. The current mfi is 72.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Zelira Therapeutics Ltd Daily Money Flow Index (MFI) ChartZelira Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zelira Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-16MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Zelira Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.759
Ma 20Greater thanMa 500.417
Ma 50Greater thanMa 1000.441
Ma 100Greater thanMa 2000.497
OpenGreater thanClose0.500
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Zelira Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Zelira Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zelira Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Zelira Therapeutics Ltd.

Receive notifications about Zelira Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.